Non-toxic and addiction free: The promise of a new pain med
December 2, 2022
Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.
Pain relief without toxicity or addiction could become a reality, and South Rampart Pharma’s father-son, surgeons-turned-entrepreneurs duo could hold the key. Dr. Hernan Bazan, CEO and co-founder of the clinical stage pain company, believes it’s on the right track to capitalize not only on a market that is predicted to be valued at $90 billion by 2026, but help the 20% of adults worldwide who suffer from chronic pain.